SCHEMBL4423323

SCHEMBL4423323

CC(NC(=O)c1ccc(OCc2ccc(F)cc2)c(F)c1)C(N)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.45
PARP10 Q53GL7 1/20 0.45
TAS1R3 Q7RTX0 1/20 0.45
TAS1R1 Q7RTX1 1/20 0.45
RAB9A P51151 3/20 0.44
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 2/20 0.44
MAPT P10636 1/20 0.44
PPARG P37231 1/20 0.44
NCOA3 Q9Y6Q9 1/20 0.44
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
HPGD P15428 1/20 0.44
NPC1 O15118 1/20 0.44
CASP3 P42574 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
MAPK14 Q16539 1/20 0.44
SMPD1 P17405 2/20 0.44
HDAC1 Q13547 2/20 0.43
HDAC8 Q9BY41 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4423318 1.00 MAOB (0.45) MAOBPARP10TAS1R3TAS1R1RAB9A
SCHEMBL3504640 0.89 MRGPRX4 (0.52) MAOBPPARG
SCHEMBL3506459 0.89 MRGPRX4 (0.52) MAOBPPARG
SCHEMBL3504638 0.89 MRGPRX4 (0.52) MAOBPPARG
SCHEMBL4422210 0.88 MAOB (0.55) MAOBPARP10MAOASCN9A
SCHEMBL4426798 0.88 MAOB (0.55) MAOBPARP10MAOASCN9A
SCHEMBL4422205 0.88 MAOB (0.55) MAOBPARP10MAOASCN9A
SCHEMBL4427468 0.85 MAOB (0.44) MAOBPARP10TAS1R3TAS1R1RAB9A
SCHEMBL4429125 0.85 MAOB (0.44) MAOBPARP10TAS1R3TAS1R1RAB9A
SCHEMBL5811691 0.81 MAOB (0.44) MAOBPARP10RAB9AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1515926-B1 FLUOROBENZAMIDES SUITABLE FOR THE TREATMENT OF ALZHEIMER'S DISEASE OR SENILE DEMENTIA HOFFMANN LA ROCHE (CH) 2009-04-08 EP claimed
US-20070078172-A1 MAO-B INHIBITORS USEFUL FOR TREATING OBESITY JENRIN DISCOVERY (US) 2007-04-05 US claimed
WO-2006138475-A2 MAO-B INHIBITORS USEFUL FOR TREATING OBESITY JENRIN DISCOVERY (US) 2006-12-28 WO claimed
US-6951884-B2 Fluorobenzamides and uses thereof HOFFMANN-LA ROCHE INC. (US) 2005-10-04 US claimed
US-20030236304-A1 Fluorobenzamides and uses thereof F. HOFFMANN-LA ROCHE AG (CH) 2003-12-25 US claimed
EP-1515926-B1 FLUOROBENZAMIDES SUITABLE FOR THE TREATMENT OF ALZHEIMER'S DISEASE OR SENILE DEMENTIA HOFFMANN LA ROCHE (CH) 2009-04-08 EP disclosed
US-20070078172-A1 MAO-B INHIBITORS USEFUL FOR TREATING OBESITY JENRIN DISCOVERY (US) 2007-04-05 US disclosed
WO-2006138475-A2 MAO-B INHIBITORS USEFUL FOR TREATING OBESITY JENRIN DISCOVERY (US) 2006-12-28 WO disclosed
US-6951884-B2 Fluorobenzamides and uses thereof HOFFMANN-LA ROCHE INC. (US) 2005-10-04 US disclosed
US-20030236304-A1 Fluorobenzamides and uses thereof F. HOFFMANN-LA ROCHE AG (CH) 2003-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236304-A1 Fluorobenzamides and uses thereof MAOB, MAOA, BCHE MAOB 1/4885PARP10 1686/4885TAS1R3 2965/4885
US-20070078172-A1 MAO-B INHIBITORS USEFUL FOR TREATING OBESITY MAOB, MAOA, GPR119 MAOB 1/4885PARP10 833/4885TAS1R3 3700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.